13234
clinical study

Enhancing Stroke Care Efficiency through AI Vendor Transition: A Comparative Study of Workflow Metrics Before and After Implementation

Materials & Methods

This retrospective analysis examined 354 acute stroke cases to compare workflow metrics before and after transitioning AI vendors. The pre-implementation phase, covering Oct. to Nov. 2022, used Vendor A (RapidAI-IschemaView), while the post-implementation phase, spanning Oct. to Nov. 2023, assessed Vendor B (Aidoc). A one-month exclusion buffer (Sept. 2023) allowed for the onboarding and implementation of the new AI system. The study measured key workflow metrics, including door-to-CTA completion time and time to intervention, to evaluate the efficiency of the AI transition.

Results

The transition to Vendor B resulted in workflow improvements across key performance metrics. The door-to-CT initiation time decreased from 18.5 minutes to 9.5 minutes, while the time from door-to-CT results improved significantly, reducing by 24% (from 29.5 to 22.5 minutes) for the neurovascular team and by 25% (from 32 to 24 minutes) for the radiology team. Although the door-to-CTA completion time showed only a slight 5% improvement, the most impactful change was the reduction in median door-to-skin puncture time, which decreased by 34% from 113 minutes to 75 minutes, aligning with the institutional target. Additionally, the number of thrombectomies performed per month doubled, increasing from 2.5 to 5 cases.

Conclusions

This study demonstrates that transitioning to a new AI vendor improved workflow efficiency in acute stroke care, particularly by reducing door-to-skin puncture time and meeting institutional benchmarks. The findings highlight the importance of selecting an AI vendor that optimally integrates with clinical workflows to maximize efficiency. Future research will focus on a more detailed analysis of the specific contributions of AI-driven workflow optimization and diagnostic capabilities in improving stroke care outcomes.

Explore the Latest AI Insights, Trends and Research

Daniel Spector

<p>Daniel Spector is an AI Transformation Consultant at Aidoc. His focus is enabling clinicians and hospital administrators to provide better, more efficient care through the power of AI augmentation for enterprise imaging.</p>

Amalia Schreier

<p>Amalia Schreier serves as the Senior Vice President of Regulatory Affairs and Legal at Aidoc, guiding our company and product’s regulatory strategies and ensuring alignment with AI-focused medical device compliance requirements. Since her tenure began, she has streamlined our FDA clearance processes, emphasizing a meticulous approach that underscores our commitment to product and clinical quality.</p> <p>With a solid foundation from her legal background and leadership role in AI startup regulatory departments, Schreier brings invaluable insights and expertise to our regulatory framework. Prior to her tech world experience, she worked as a human-rights lawyer and legal policy scholar, with a BA and LLM in law from the Hebrew University of Jerusalem.</p>

Deepak Srikant

<p>Deepak Srikant is a global marketing executive with over 20 years of experience, specializing in the commercialization of medical devices and digital health solutions. He has a proven track record in driving growth, having led successful go-to-market strategies, product launches and market expansions across the U.S. and EMEA.</p> <p>Srikant’s expertise extends to upstream and downstream marketing, professional education and sales enablement. His leadership at companies such as Silk Road Medical (acquired by Boston Scientific) and Aptus Endosystems (acquired by Medtronic) has consistently resulted in revenue growth, enhanced customer retention and successful product adoption.</p> <p>Srikant holds an MBA from the Yale School of Management and a bachelor’s degree in mechanical engineering from Rensselaer Polytechnic Institute. Currently, he leads product marketing for Aidoc’s cardiovascular service line.</p>